Synonym
Vapiprost hydrochloride; GR 32191B; GR-32191B; GR32191B; Vapiprost HCl;
IUPAC/Chemical Name
4-Heptenoic acid, 7-(5-((1,1'-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, hydrochloride, (1R-(1alpha(Z),2beta,3beta,5alpha))-
InChi Key
ZYOBZRTZRQKKNC-UGNABIHOSA-N
InChi Code
InChI=1S/C30H39NO4.ClH/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31;/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34);1H/b2-1-;/t26-,27-,28-,30+;/m0./s1
SMILES Code
O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCC3=CC=C(C4=CC=CC=C4)C=C3.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
514.10
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cracowski JL, Stanke-Labesque F, Devillier P, Chavanon O, Hunt M, Souvignet C, Bessard G. Human internal mammary artery contraction by isoprostaglandin f(2alpha) type-III [8-iso-prostaglandin F(2alpha)]. Eur J Pharmacol. 2000 May 26;397(1):161-8. PubMed PMID: 10844110.
2: Barchasz E, Naline E, Molimard M, Moreau J, Georges O, Emonds-Alt X, Advenier C. Interleukin-1beta-induced hyperresponsiveness to [Sar9,Met(O2)11]substance P in isolated human bronchi. Eur J Pharmacol. 1999 Aug 20;379(1):87-95. PubMed PMID: 10499376.
3: Horie S, Yamada M, Satoh M, Noritake S, Hiraishi S, Kizaki K, Kurusu O, Nakahara T, Ishii H, Kazama M. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Biol Pharm Bull. 1997 Jun;20(6):625-31. PubMed PMID: 9212979.
4: Molimard M, Martin CA, Naline E, Hirsch A, Advenier C. Role of thromboxane A2 in bradykinin-induced human isolated small bronchi contraction. Eur J Pharmacol. 1995 May 4;278(1):49-54. PubMed PMID: 7545124.
5: Ogletree ML, Allen GT. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther. 1992 Feb;260(2):789-94. PubMed PMID: 1531361.
6: Takahara K, Murray R, FitzGerald GA, Fitzgerald DJ. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem. 1990 Apr 25;265(12):6836-44. PubMed PMID: 2139029.
